文献速递妇科

平滑肌瘤与平滑肌肉瘤中高水平的hypusinated eIF5A:一个可能的新治疗靶点

High levels of hypusinated eIF5A in leiomyoma and leiomyosarcoma pathologies: a possible novel therapeutic target.
PubMed 文献 · Reprod Biomed Online · 2023-03-27

研究检测了人子宫肌层、平滑肌瘤和平滑肌肉瘤中hypusinated eIF5A的表达,并用GC-7抑制eIF5A hypusination后观察细胞增殖与纤连蛋白表达。结果显示hypusinated eIF5A在所有组织中存在,从正常子宫肌层到平滑肌瘤再到平滑肌肉瘤呈升高趋势,抑制后可降低多种细胞系增殖及平滑肌瘤和平滑肌肉瘤细胞的纤连蛋白表达。

要点

  • hypusinated eIF5A在正常子宫肌层、平滑肌瘤和平滑肌肉瘤中均存在,且从正常到良性肿瘤再到恶性肿瘤呈升高趋势。
  • 100 nM GC-7抑制eIF5A hypusination后,可降低子宫肌层、平滑肌瘤和平滑肌肉瘤细胞系的增殖。
  • GC-7处理降低平滑肌瘤和平滑肌肉瘤细胞中纤连蛋白表达,平滑肌肉瘤组织中央侵袭部位高表达纤连蛋白且hypusinated eIF5A也高表达。

核心结论

  • 这些数据支持eIF5A可能参与子宫肌层良性和恶性病理过程的发病机制这一假设。

研究设计与样本

  • 研究采用患者匹配的子宫肌层与平滑肌瘤组织,通过免疫组织化学和蛋白质印迹评估eIF5A的hypusination状态,并对平滑肌肉瘤组织进行免疫组织化学检测。
  • 用N1-胍基-1,7-二氨基庚烷(GC-7)处理子宫肌层、平滑肌瘤和平滑肌肉瘤细胞系以抑制eIF5A hypusination的第一步,用MTT法测定增殖率,用蛋白质印迹分析纤连蛋白表达。
  • 通过免疫组织化学检测平滑肌肉瘤组织中纤连蛋白的表达。

主要发现

  • hypusinated eIF5A存在于所有受检组织中,从正常子宫肌层到良性肿瘤平滑肌瘤直至恶性肿瘤平滑肌肉瘤,hypusinated eIF5A水平呈升高趋势。
  • 蛋白质印迹证实平滑肌瘤中hypusinated eIF5A水平高于子宫肌层(P = 0.0046)。
  • 100 nM GC-7抑制eIF5A hypusination后,子宫肌层细胞系增殖降低(P = 0.0429),平滑肌瘤细胞系增殖降低(P = 0.0030),平滑肌肉瘤细胞系增殖降低(P = 0.0044)。
  • GC-7处理降低平滑肌瘤细胞纤连蛋白表达(P = 0.0077)和平滑肌肉瘤细胞纤连蛋白表达(P = 0.0280)。
  • 平滑肌肉瘤组织免疫组化显示,纤连蛋白在恶性侵袭性(中央)部位高表达,该部位hypusinated eIF5A也高表达。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RESEARCH QUESTION: Is the hypusinated form of the eukaryotic translation initiation factor 5A (EIF5A) present in human myometrium, leiomyoma and leiomyosarcoma, and does it regulate cell proliferation and fibrosis? DESIGN: The hypusination status of eIF5A in myometrial and leiomyoma patient-matched tissues was evaluated by immunohistochemistry and Western blotting as well as in leiomyosarcoma tissues by immunohistochemistry. Myometrial, leiomyoma and leiomyosarcoma cell lines were treated with N1-guanyl-1,7-diaminoheptane (GC-7), responsible for the inhibition of the first step of eIF5A hypunization, and the proliferation rate was determined by MTT assay; fibronectin expression was analysed by Western blotting. Finally, expression of fibronectin in leiomyosarcoma tissues was detected by immunohistochemistry. RESULTS: The hypusinated form of eIF5A was present in all tissues examined, with an increasing trend of hypusinated eIF5A levels from normal myometrium to neoplastic benign leiomyoma up to neoplastic malignant leiomyosarcoma. The higher levels in leiomyoma compared with myometrium were confirmed by Western blotting (P = 0.0046). The inhibition of eIF5A hypusination, with GC-7 treatment at 100 nM, reduced the cell proliferation in myometrium (P = 0.0429), leiomyoma (P = 0.0030) and leiomyosarcoma (P = 0.0044) cell lines and reduced the expression of fibronectin in leiomyoma (P = 0.0077) and leiomyosarcoma (P = 0.0280) cells. The immunohistochemical staining of leiomyosarcoma tissue revealed that fibronectin was highly expressed in the malignant aggressive (central) part of the leiomyosarcoma lesion, where hypusinated eIF5A was also highly represented. CONCLUSIONS: These data support the hypothesis that eIF5A may be involved in the pathogenesis of myometrial benign and malignant pathologies.

来源:Reprod Biomed Online,查看原文。版权归原作者所有。

引用

  1. Greco S, Zannotti A, Pellegrino P, et al. High levels of hypusinated eIF5A in leiomyoma and leiomyosarcoma pathologies: a possible novel therapeutic target. Reprod Biomed Online. 2023. PMID: 37137790. doi:10.1016/j.rbmo.2023.03.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。